Cincinnati, Ohio (June 8, 2017)
M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB:T3F2 ), (the “Company” or “M Pharma”), today announced that Gary Stephens is joining this global healthcare company as its new Chief Financial Officer (CFO), effective Immediately. Mr. Stephens brings with him an extensive background in corporate finance, treasury planning and analysis, strategic planning and risk management along with a deep appreciation for M Pharma’s unique position driving global health and wellness.
“It is a pleasure to welcome Gary to the M Pharma team where he will undoubtedly make an immediate impact as we continue to align all corporate operations within the Cincinnati metro area,” said Gary Thompson, President & CEO of M Pharmaceutical Inc.
“Gary has been deeply involved in several of the private companies that originally held the assets recently acquired by M Pharma,” added Mr. Thompson. “Because of this past level of understanding with the M Pharma technology portfolio, Mr. Stevens is in an unique position to help up tackle the many opportunities to improve our efficiency and performance,” added Thompson.
Gary Stephens is a Certified Public Accountant and is licensed in the states of Kentucky and Ohio. Gary has over 35 years experience in public accounting and has assisted companies with their initial public offerings, SEC filings and annual reporting to shareholders.
Unlike the other two drugs approved by the US FDA to treat FSD, the company’s topical drug product, Extrinsa, would focus on women with orgasm and arousal difficulties. Valeant’s Addyi, recently acquired from Sprout Pharmaceuticals, is indicated only for HSDD (desire disorder) with a number of FDA imposed prescription and marketing restrictions. Intrarosa, by Endoceutics, is indicated for dyspareunia (pain with intercourse) with certain prescribing restrictions. M Pharma’s Extrinsa treatment is topical, local and non-systemic, with daily and on demand use, while being non-hormonal and not a central nervous system drug. Based on these core attributes, the safety profiles of the API and excipients in the drug product, and the dosage and delivery form, the company anticipates Extrinsa to be extremely well-tolerated and highly effective for many women suffering from FSD and has a great likelihood of ultimate approval by the FDA.
About Callitas Therapeutics
Formerly M Pharmaceutical Inc., Callitas Therapeutics was formed in early 2015, is a clinical-stage company developing innovative technologies for obesity, weight management and Female Health & Wellness. In addition to its recent acquisitions of C-103, a reformulation of orlistat from Chelatexx, LLC and assets from 40J’s LLC including Extrinsa, the Company is scheduled to launch their FDA cleared fertility product branded as ToConceive in July of this year.
M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”
For more information contact:
Phone: +1 (859) 868-3131
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval, commercialization of the rights to the Company’s biomedical & drug technologies, and acquisition of new products. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices: C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.